Bear thanks for the links to the previous posts on CKD. 30 million American's with CKD at an annual cost of $48 billion is a pretty darn big market to play in. I think I read that in all of Europe there was 54 million people with CKD back in March when these posts made it to this board. I may however be confusing that number of people in Europe with CKD with the number of people with diabetes. Since we are playing in both sandboxes it represents a lot of potential patients that may be able to use ABL some day for one or more of their ailments. 

The CKD fact sheat on the second link was really good to reread and the last point kind of says it all; Chronic kidney disease can be treated. With early diagnosis and treatment, it's possible to slow or stop the progression of kidney disease. I also remember reading an article that you posted in the past about the number of people in the US that were not diagnosed with CKD that in fact did have the disease. That number of undiagnosed patients I think was more than 25% of the diagnosed patients.

If ABL is able to slow or even reverse this disease to some extent in a safe manor the potential market is extremely large.

I have wondered for the last couple of years now whether ABL should have been developed as a drug for CKD instead of for CVD.

tada